A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To study the anti-HIV activity of the various doses of Ro 24-7429 monotherapy based on virologic and immunologic endpoints. To study the safety and tolerance of Ro 24-7429. To explore relationships between exposure to Ro 24-7429 and its metabolites and antiviral activity and drug toxicity. To determine a safe, tolerable, and active dose regimen of Ro 24-7429, and to make preliminary observations of Ro 24-7429 in combination with another antiretroviral nucleoside.
The HIV genome contains a number of genes that regulate viral replication. Control of the activity of these genes and their encoded proteins represents a potential target for development of new antiretroviral drugs. The tat (transactivator of transcription of HIV) antagonist Ro 24-7429 is the first compound for clinical testing that utilizes this approach for therapy of HIV infection.
| Condition | Intervention | Phase |
|---|---|---|
|
HIV Infections |
Drug: Ro 24-7429 Drug: Zidovudine Drug: Didanosine |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Primary Purpose: Treatment |
| Official Title: | A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection |
| Estimated Enrollment: | 96 |
The HIV genome contains a number of genes that regulate viral replication. Control of the activity of these genes and their encoded proteins represents a potential target for development of new antiretroviral drugs. The tat (transactivator of transcription of HIV) antagonist Ro 24-7429 is the first compound for clinical testing that utilizes this approach for therapy of HIV infection.
Ninety-six patients (four treatment arms of 24 patients each) are randomized to receive oral Ro 24-7429 at 1 of 3 doses or nucleoside control (either zidovudine or didanosine). The study will be blinded only for the arms receiving Ro 24-7429. Treatment continues for 12 weeks. After 12 weeks, patients on the nucleoside control arm receive the highest tolerated dose of Ro 24-7429 in addition to their nucleoside.
Eligibility| Ages Eligible for Study: | 12 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
- Chemoprophylaxis for P. carinii pneumonia, TB, and mucocutaneous candidiasis.
- Methadone maintenance.
- Hormonal contraceptives.
Patients must have:
- HIV-1 seropositivity.
- CD4 count 50 - 500 cells/mm3.
- Life expectancy of at least 24 weeks.
- Stable weight (+/- 2 kg) by 28 days prior to study entry (by history).
NOTE:
- At least 50 percent of patients must be p24 antigen positive (>= 50 pg/ml).
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
- Known or suspected hypersensitivity to benzodiazepines.
- Presence of any malignancy other than basal cell carcinoma or limited cutaneous Kaposi's sarcoma (defined as no more than five lesions with no mucosal involvement).
- Ongoing diarrhea, defined as more than 2 liquid stools per day.
- History, physical exam, or laboratory results consistent with a subclinical AIDS-defining opportunistic infection.
- Grade 2 or greater signs and symptoms of AIDS Dementia Complex.
- Evidence of clinically significant cardiac, respiratory, hepatic, gastrointestinal, endocrine, hematologic, psychiatric, neurologic, dermatologic, or allergic disease.
Concurrent Medication:
Excluded:
- Chronic suppressive therapy for CMV, MAI, toxoplasmosis, cryptococcosis, cryptosporidiosis, coccidioidomycosis, and histoplasmosis.
- ddC, ddI, AZT (except for control groups) or other experimental antiretrovirals or immunomodulating agents.
- Other medications excluded from the study.
Patients with the following prior conditions are excluded:
- History of serious adverse reactions to benzodiazepines.
- History of intolerance to AZT at 600 mg/day or less or ddI at 400 mg/day or less.
- History of unexplained fever, defined as a temperature of 38.5 deg C or greater with or without night sweats for more than 7 of the past 28 days.
Prior Medication:
Excluded:
- Benzodiazepines within 14 days prior to study entry.
Active drug or alcohol abuse that would interfere with study compliance.
Contacts and Locations| United States, California | |
| UCSD | |
| San Diego, California, United States, 92103 | |
| United States, Maryland | |
| Johns Hopkins Hosp | |
| Baltimore, Maryland, United States, 21205 | |
| United States, Massachusetts | |
| Harvard (Massachusetts Gen Hosp) | |
| Boston, Massachusetts, United States, 02114 | |
| United States, Ohio | |
| Case Western Reserve Univ | |
| Cleveland, Ohio, United States, 44106 | |
| Study Chair: | Richman DD | |
| Study Chair: | Haubrich R |
More Information
Additional Information:
Publications:
| ClinicalTrials.gov Identifier: | NCT00000760 History of Changes |
| Other Study ID Numbers: | ACTG 213, NV14224A |
| Study First Received: | November 2, 1999 |
| Last Updated: | July 31, 2008 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
|
Didanosine Acquired Immunodeficiency Syndrome AIDS-Related Complex |
Antiviral Agents Zidovudine Gene Products, tat |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Didanosine |
Zidovudine Antimetabolites Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Therapeutic Uses Anti-HIV Agents |
ClinicalTrials.gov processed this record on May 23, 2013